GlassScriptPhysician profile
Lindsey Campion
NPI 1497372262
$1,255.27
in general payments reported to CMS, 2019-2025
14 companies · $15.18 in 2025
The $15.18 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5.01 · 2023: $877 · 2024: $358 · 2025: $15.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,250.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $781.11 | 2023-2024 | |
| Pfizer INC. | $99.97 | 2023-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $71.75 | 2023-2024 | Caplyta |
| Novo Nordisk INC | $51.32 | 2023-2024 | |
| C. R. Bard, INC. & Subsidiaries | $44.19 | 2023 | Bd Affirm Vpiii Microbial Identification Test |
| Lilly USA, LLC | $43.09 | 2023-2024 | Mounjaro |
| Hologic Sales and Service, LLC | $39.99 | 2023 | Thinprep 2000 Processor, Aptima |
| Idorsia Pharmaceuticals US INC | $25.79 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $22.88 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.51 | 2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $19.18 | 2023 | Abilify Maintena, Rexulti |
| Organon LLC | $16.30 | 2023 | Nexplanon |
| Astrazeneca Pharmaceuticals LP | $15.18 | 2025 | |
| Genentech USA, INC. | $5.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Campion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.